You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for CPPG
CPPG is a potent group II/III mGlu receptor antagonist, with approximately 20-fold selectivity for group III over group II (IC50 values of 2.2 and 46.2 nM respectively). A much less potent antagonist at group I receptors in neonatal rat cortical slices (KB = 0.65 ± 0.07 nM).
Technical Data for CPPG
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for CPPG
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for CPPG
The following data is based on the product molecular weight 271.21. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.69 mL||18.44 mL||36.87 mL|
|5 mM||0.74 mL||3.69 mL||7.37 mL|
|10 mM||0.37 mL||1.84 mL||3.69 mL|
|50 mM||0.07 mL||0.37 mL||0.74 mL|
References for CPPG
References are publications that support the biological activity of the product.
Jane et al (1996) Potent antagonists at the L-AP4- and (1S, 3S)-ACPD-sensitive presynaptic metabotropic glutamate receptors in the neonatal rat spinal cord. Neuropharmacology 35 1029 PMID: 9121605
Toms et al (1996) The effects of (RS)-α-cyclopropyl-4-phosphonophenylglycine ((RS)-CPPG), a potent and selective metabotropic glutamate receptor antagonist. BrJ.Pharmacol. 119 851 PMID: 8922731
Kemp et al (1996) α-Methyl-3-phosphonophenylglycine and α-cyclopropyl-4-phosphonophenylglycine are potent antagonists at mGluRs negatively coupled to adenylyl cyclase. Br.J.Pharmacol. 117 (in press)
If you know of a relevant reference for CPPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: CPPG, CPPG supplier, potent, group, III, Antagonists, Group, Receptors, mGlu4, mGlu6, mGlu7, mGlu8, mGlu4R, mGlu6R, mGlu7R, mGlu8R, Glutamate, Metabotropic, (Metabotropic), 0972, Tocris Bioscience
21 Citations for CPPG
Citations are publications that use Tocris products. Selected citations for CPPG include:
Zhang et al (2010) RGS7 and -11 complexes accelerate the ON-bipolar cell light response. Invest Ophthalmol Vis Sci 51 1121 PMID: 19797214
Dornier (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nat Commun 8 2255 PMID: 29269878
Spampinato et al (2015) Glial metabotropic glutamate receptor-4 increases maturation and survival of oligodendrocytes. Neurotox Res 8 462 PMID: 25642169
He et al (2012) Increased Kv1 channel expression may contribute to decreased sIPSC frequency following chronic inhibition of NR2B-containing NMDAR. Neuropsychopharmacology 37 1338 PMID: 22218089
Broadstock et al (2012) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol 165 1034 PMID: 21627638
Cassé et al (2012) Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci 32 5186 PMID: 22496564
Rancillac et al (2006) Glutamatergic Control of Microvascular Tone by Distinct GABA Neurons in the Cerebellum. J Neurosci 26 6997 PMID: 16807329
Ichinose and Lukasiewicz (2012) The mode of retinal presynaptic inhibition switches with light intensity. J Neurosci 32 4360 PMID: 22457487
Jiang et al (2006) Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on DArgic neurons through a microtubule-dependent mechanism. J Neurosci 26 4318 PMID: 16624952
Newman (2005) Calcium increases in retinal glial cells evoked by light-induced neuronal activity. Front Cell Neurosci 25 5502 PMID: 15944378
Bennett et al (2014) Examination of VLC-PUFA-deficient photoreceptor terminals. J Neurosci 55 4063 PMID: 24764063
Domin et al (2014) Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivo. Proc Natl Acad Sci U S A 26 99 PMID: 24402869
Balakrishnan et al (2009) Slow glycinergic transmission mediated by transmitter pooling. Nat Neurosci 12 286 PMID: 19198604
Mathiesen et al (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138 1026 PMID: 12684257
Nishi et al (2003) Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Invest Ophthalmol Vis Sci 100 1322 PMID: 12538871
Collard et al (2002) Neutrophil-derived glutamate regulates vascular endothelial barrier function. J Biol Chem 277 14801 PMID: 11847215
Nieus et al (2014) Regulation of output spike patterns by phasic inhibition in cerebellar granule cells. Front Cell Neurosci 8 246 PMID: 25202237
De-May and Ali (2013) Cell type-specific regulation of inhibition via cannabinoid type 1 receptors in rat neocortex. J Neurophysiol 109 216 PMID: 23054605
Hellmer et al (2018) A group I metabotropic glutamate receptor controls synaptic gain between rods and rod bipolar cells in the mouse retina. Physiol Rep 6 e13885 PMID: 30338673
Tassin et al (2016) Phasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical Network. Front Neural Circuits 10 31 PMID: 27199672
Ali (2011) CB1 modulation of temporally distinct synaptic facilitation among local circuit interneurons mediated by N-type calcium channels in CA1. J Neurophysiol 105 1051 PMID: 21123660
Do you know of a great paper that uses CPPG from Tocris? Please let us know.
Reviews for CPPG
Average Rating: 5 (Based on 2 Reviews.)
Have you used CPPG?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Retinal dissections were performed in HEPES-buffered extracellular solution containing glutamate inhibitor cocktail - 600 umol/L
CPPG (5 microM) was used for pharmacological isolation of GABA-A receptor activity in nucleated membrane patches. Being added to perfusion solution, CPPG blocked contaminating receptor activity in a recorded response, thus revealing clear GABA-ergic single-channel openings. Figure: single-channel openings of GABA-A receptors in a membrane patch after application of CPPG.
Compound should be sonicated when dissolving.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.